Purpose: Because of concern for drug-induced cognitive dysfunction during clinical trials using substrate reduction therapy (miglustat) in type 1 Gaucher disease and because it has been suggested that ...

Disclosure: C. Thomas Gualtieri, MD, has disclosed that he has conducted clinical trials on behalf of AstraZeneca, Bristol-Myers Squibb, Celltech, Cephalon, Eli Lilly, GlaxoSmithKline, Medeva, Organon ...

BUFFALO, N.Y. -- A new version of a reliable and well-regarded dimensional test for personality disorders developed by a University at Buffalo researcher and clinician may lead to clearer diagnosis of ...

As the global population ages, the rate of dementia is increasing worldwide. Given that early detection is critical for treatment, effective ways to screen for dementia are a high research priority.

A targeted computerized alert at the time of physician order entry reduced the use of D-dimer testing among patients 65 years and older. A single-crossover cluster randomized trial of computerized ...